Fleishman-Hillard launches managed-markets division

Share this article:

Fleishman-Hillard is moving to cash in on the shift to managed markets with a new healthcare public affairs shop headed by Anne Woodbury, an associate of former Speaker Newt Gingrich, and Sharad Mansukani, one of the architects of the Medicare Modernization Act.
The Omnicom Group company is opening Fleishman-Hillard Health Solutions Navigator, a Washington, D.C., unit offering regulatory and policy communications, reimbursement consulting and media and government relations services including public opinion research, grassroots and coalition development, corporate and cause partnerships, issue
advertising and large-scale public education programs.  
Mansukani was a senior advisor and medical officer at the Center for Medicare and Medicaid Services, and served on the Bush Administration's Medicare Modernization Executive Committee. His focus at CMS was on prescription drug benefits, managed care enhancements and disease-management efforts, along with improving collaboration between CMS, the FDA and the NIH.
Woodbury, a longtime Gingrich aide, was most recently chief health advocate for the former House speaker's Center for Health Transformation.


Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...